Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | -11.02% | -9.17% | -5.22% |
Apr. 26 | Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro | CI |
Apr. 19 | Top Premarket Decliners | MT |
Valuation
Fiscal Period: March | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Capitalization 1 | 54.42 | 128.1 | 133 | 27.83 | 10.32 | - |
Enterprise Value (EV) 1 | 54.42 | 128.1 | 133 | 27.83 | 10.32 | 10.32 |
P/E ratio | -3.54 x | -5.47 x | -3.41 x | - | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | 17.4 x | 2.89 x | 0.86 x | 0.72 x |
EV / Revenue | - | - | 17.4 x | 2.89 x | 0.86 x | 0.72 x |
EV / EBITDA | - | - | -7,777,400 x | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 9,967 | 8,911 | 9,768 | 9,975 | 9,469 | - |
Reference price 2 | 5.460 | 14.37 | 13.62 | 2.790 | 1.090 | 1.090 |
Announcement Date | 7/16/19 | 6/22/21 | 7/14/22 | 6/29/23 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: March | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | 7.65 | 9.639 | 12 | 14.3 |
EBITDA | - | - | -17.11 | - | - | - |
EBIT 1 | - | - | -18.02 | -15.41 | -7.2 | -4.9 |
Operating Margin | - | - | -235.55% | -159.87% | -60% | -34.27% |
Earnings before Tax (EBT) | - | - | -29.13 | - | - | - |
Net income | -8.592 | -15.49 | -30.22 | - | - | - |
Net margin | - | - | -395.01% | - | - | - |
EPS | -1.542 | -2.628 | -3.990 | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 7/16/19 | 6/22/21 | 7/14/22 | 6/29/23 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: March | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 1.807 | 1.93 | 2.149 | 2.056 | 2.381 | 2.459 | 2.742 | 3.021 | 2.891 | 2.973 | 3.2 |
EBITDA | -4.999 | -4.635 | -4.626 | -4.385 | -4.287 | -4.112 | - | - | - | - | - |
EBIT 1 | -5.169 | -4.735 | -5.114 | -4.477 | -4.433 | -4.252 | -3.454 | -2.316 | -2.186 | -1.282 | -1.4 |
Operating Margin | -286% | -245.34% | -237.99% | -217.75% | -186.13% | -172.9% | -125.93% | -76.69% | -75.59% | -43.11% | -43.75% |
Earnings before Tax (EBT) | -10.75 | -7.11 | -5.612 | -4.776 | -4.693 | -4.517 | - | - | - | - | - |
Net income | -11 | -7.343 | -5.982 | -5.024 | -4.904 | -4.747 | - | - | - | - | - |
Net margin | -608.5% | -380.44% | -278.38% | -244.37% | -205.95% | -193.05% | - | - | - | - | - |
EPS | -1.536 | -0.8940 | -0.6660 | -0.5880 | -0.5640 | -0.5460 | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/4/21 | 2/14/22 | 7/14/22 | 8/15/22 | 11/14/22 | 2/14/23 | 6/29/23 | 8/14/23 | 11/14/23 | 2/20/24 | - |
Balance Sheet Analysis
Fiscal Period: March | 2019 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 7/16/19 | 6/22/21 | 7/14/22 | 6/29/23 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-5.22% | 11.6M | |
-7.63% | 3.08B | |
-5.53% | 172M | |
-14.03% | 85.92M | |
-45.91% | 51.5M |
- Stock Market
- Equities
- BTCY Stock
- Financials Biotricity, Inc.